Jeff Lande

Jeff Lande

Auto-generated profile, based on publicly available information

Jeff Lande

Medtronic Inc, Mounds View, MN (C.W., J.D.L., J.L., A.E.T., T.R.H.).

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Open access
PDF file
BWBruce L Wilkoff
Bruce L Wilkoff
Giuseppe BorianiGiuseppe Boriani
Giuseppe Boriani
SMSuneet Mittal
Suneet Mittal
JPJeanne E Poole
Jeanne E Poole
CKCharles Kennergren
Charles Kennergren
KTKhaldoun G Tarakji
Khaldoun G Tarakji
Background: Current understanding of the impact of cardiac implantable electronic device (CIED) infection is based on retrospective analyses from medical records or administrative claims data. The WRAP-IT (Worldwide Randomized Antibiotic Envelope Infection Prevention Trial) offers an opportunity to evaluate the clinical and economic impacts of CIED infection from the hospital, payer, and patient perspectives in the US healthcare system. Methods: This was a prespecified, as-treated analysis evaluating outcomes related to major CIED infections: mortality, quality of life, disruption of CIED therapy, healthcare utilization, and costs. Payer costs were assigned using medicare fee for service national payments, while medicare advantage, hospital, and patient costs were derived from similar hospital admissions in administrative datasets. Results: Major CIED infection was associated with increased all-cause mortality (12-month risk-adjusted hazard ratio, 3.41 [95% CI, 1.81–6.41]; P <0.001), an effect that sustained beyond 12 months (hazard ratio through all follow-up, 2.30 [95% CI, 1.29–4.07]; P =0.004). Quality of life was reduced ( P =0.004) and did not normalize for 6 months. Disruptions in CIED therapy were experienced in 36% of infections for a median duration of 184 days. Mean costs were $55 547±$45 802 for the hospital, $26 867±$14 893, for medicare fee for service and $57 978±$29 431 for Medicare Advantage (mean hospital margin of −$30 828±$39 757 for medicare fee for service and −$6055±$45 033 for medicare advantage). Mean out-of-pocket costs for patients were $2156±$1999 for medicare fee for service, and $1658±$1250 for medicare advantage. Conclusions: This large, prospective analysis corroborates and extends understanding of the impact of CIED infections as seen in real-world datasets. CIED infections severely impact mortality, quality of life, healthcare utilization, and cost in the US healthcare system. Registration: URL: https://www.clinicaltrials.gov Unique Identifier: NCT02277990

1 October 2020 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Open access
PDF file
BWBruce L. Wilkoff
Bruce L. Wilkoff
Giuseppe BorianiGiuseppe Boriani
Giuseppe Boriani
SMSuneet Mittal
Suneet Mittal
JPJeanne E. Poole
Jeanne E. Poole
CKCharles Kennergren
Charles Kennergren
KTKhaldoun G. Tarakji
Khaldoun G. Tarakji
Background - In the WRAP-IT trial, adjunctive use of an absorbable antibacterial envelope resulted in a 40% reduction of major cardiac implantable electronic device (CIED) infection without increased risk of complication in 6,983 patients undergoing CIED revision, replacement, upgrade, or initial cardiac resynchronization therapy defibrillator (CRT-D) implant. There is limited information on the cost-effectiveness of this strategy. As a pre-specified objective, we evaluated antibacterial envelope cost-effectiveness compared to standard-of-care infection prevention strategies in the US healthcare system. Methods - A decision tree model was used to compare costs and outcomes of antibacterial envelope (TYRX) use adjunctive to standard-of-care infection prevention vs. standard-of-care alone over a lifelong time horizon. The analysis was performed from an integrated payer-provider network perspective. Infection rates, antibacterial envelope effectiveness, infection treatment costs and patterns, infection-related mortality, and utility estimates were obtained from the WRAP-IT trial. Life expectancy and long-term costs associated with device replacement, follow-up, and healthcare utilization were sourced from the literature. Costs and quality-adjusted life years (QALYs) were discounted at 3%. An upper willingness-to-pay (WTP) threshold of $150,000 per QALY was used to determine cost-effectiveness, in alignment with American College of Cardiology and American Heart Association (ACC/AHA) practice guidelines and as supported by the World Health Organization (WHO) and contemporary literature. Results - The base-case incremental cost-effectiveness ratio (ICER) of the antibacterial envelope compared to standard-of-care was $112,603/QALY. The ICER remained lower than the WTP threshold in 74% of iterations in the probabilistic sensitivity analysis and was most sensitive to the following model inputs: infection-related mortality, life expectancy, and infection cost. Conclusions - The absorbable antibacterial envelope was associated with a cost-effectiveness ratio below contemporary benchmarks in the WRAP-IT patient population, suggesting that the envelope provides value for the US healthcare system by reducing the incidence of CIED infection.

5 October 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
ICIan Crozier
Ian Crozier
HHHaris Haqqani
Haris Haqqani
EKEmily Kotschet
Emily Kotschet
CWChristopher Wiggenhorn
Christopher Wiggenhorn
JLJeff Lande
Jeff Lande
DODavid O’dOnnell
David O’dOnnell
Anteroposterior (left) and lateral (right) fluoroscopic images of fully implanted EV ICD system in situ. Image modified from Crozier et al.8

5 April 2023 in Cardiovascular Digital Health Journal
Verified
Journal Article
Open access
ECEdmond M. Cronin
Edmond M. Cronin
JGJoseph C. Green
Joseph C. Green
JLJeff Lande
Jeff Lande
THThomas R. Holmes
Thomas R. Holmes
DLDaniel Lexcen
Daniel Lexcen
TTTyler Taigen
Tyler Taigen
Remote monitoring of cardiac implantable electric devices improves patient outcomes and experiences. Alert-based systems notify physicians of clinical or device issues in near real-time, but their effectiveness is contingent upon device connectivity. To assess patient connectivity by analyzing alert transmission times from patient transceivers to the CareLink network. Alert transmissions were retrospectively gathered from a query of the United States de-identified Medtronic CareLink database. Alert transmission time was defined as the duration from alert occurrence to arrival at the CareLink network and was analyzed by device type, alert event, and alert type. Using data from previous studies, we computed the benefit of daily connectivity checks. The mean alert transmission time was 14.8 hours (median = 6 hours), with 90.9% of alert transmissions received within 24 hours. Implantable pulse generators (17.0 ± 40.2 hours) and cardiac resynchronization therapy-pacemakers (17.2 ± 42.5 hours) had longer alert transmission times than implantable cardioverter-defibrillators (13.7 ± 29.5 hours) and cardiac resynchronization therapy-defibrillators (13.5 ± 30.2 hours), but the median time was 6 hours for all 4 device types. There were differences in alert times between specific alert events. Based on our data and previous studies, daily connectivity checks could improve daily alert transmission success by 8.5% but would require up to nearly 800 additional hours of staff time on any given day. Alert transmission performance from Medtronic devices was satisfactory, with some delays likely underscored by patient connectivity issues. Daily connectivity checks could provide some improvement in transmission success at the expense of increased clinic burden.

1 May 2021 in JACC
Verified
Journal Article
Closed access
KTKhaldoun G. Tarakji
Khaldoun G. Tarakji
PKPanagiotis Korantzopoulos
Panagiotis Korantzopoulos
FPFrancois Philippon
Francois Philippon
Mauro BiffiMauro Biffi
Mauro Biffi
SMSuneet Mittal
Suneet Mittal
BWBruce Wilkoff
Bruce Wilkoff

10 November 2026 in Circulation
Verified
Journal Article
Open access
LBLucas V.A. Boersma
Lucas V.A. Boersma
AAAnish Amin
Anish Amin
FMFrancis Murgatroyd
Francis Murgatroyd
MSMaciej Sterliński
Maciej Sterliński
JJJens Brock Johansen
Jens Brock Johansen
ICIan Crozier
Ian Crozier
BACKGROUND: The extravascular implantable cardioverter defibrillator (EV-ICD) was developed to provide defibrillation and antitachycardia pacing therapy without the need for intravascular lead placement. Premarket clinical trials reported EV-ICD safety and efficacy through 3 years, but a real-world assessment of the Aurora EV-ICD system, which includes a novel sensing discriminator, is needed. The objective of this analysis was to assess real-world therapy efficacy and safety of the EV-ICD through 1 year. METHODS: Enlighten: The EV-ICD Post Approval Registry is a prospective, global, real-world registry that included patients who underwent an EV-ICD implantation attempt. The main safety analysis was freedom from all system- or procedure-related major complications through 1 year. Event rates at 1 year were calculated using the Kaplan-Meier method. RESULTS: EV-ICD system implantation was attempted by 168 implanters in 787 patients (49.1±15.2 years old; 28.7% women; 34.1% secondary prevention). Tunneling and lead placement in the substernal space were achieved in 781 of 787 patients (99.2%), with 758 patients (96.3%) remaining implanted following defibrillation and electrical testing. One-year freedom from major system- or procedure-related complications was 89.1% (95% CI, 86.3%–91.3%). The 1-year rate of first appropriate therapy (shock, antitachycardia pacing, or both) was 7.3% (95% CI, 5.5–9.6). Shock success for discrete spontaneous episodes was 100% (61 of 61), and the generalized estimating equations antitachycardia pacing success rate, to account for multiple episodes per patient, was 74.2% for monomorphic ventricular tachycardia. The 1-year rate of first inappropriate shock was 7.1% (95% CI, 5.4–9.4), with noncardiac oversensing as the main cause (40.5% of inappropriately shocked episodes). CONCLUSIONS: In the largest prospective worldwide cohort of patients with an EV-ICD to date, both antitachycardia pacing and shock therapy were effective, while the rate of major complications agreed with the premarket experience through 1 year. These data demonstrate that positive outcomes of the EV-ICD are retained in everyday clinical practice in a large, global cohort with an expanded number of implanters. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06048731.